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Introduction {#sec1}
============

Parkinson disease (PD) is one of the most common neurodegenerative disorders, and PD patients display progressive motor dysfunction such as tremor, bradykinesia, rigidity and postural instability due to a preferential loss of dopaminergic (DA) neurons in the substantia nigra (SN) ([@bib9]). While the majority of PD cases are sporadic, approximately 10% of cases ([@bib51]) are explained by the dysregulation of proteins including PARKIN (PARK2) ([@bib24], [@bib29]), PTEN-induced putative kinase 1 (PINK1 or PARK6) ([@bib50]), α-synuclein (PARK1/4) ([@bib34]), and leucine-rich repeat serine/threonine protein kinase 2 (LRRK2 or PARK8) ([@bib18], [@bib56]). These forms of familial PD have been providing important insights into the pathogenesis of PD and have opened up new areas of investigation. For example, PD-related genes such as *PINK1* (*PARK6*) and *PARKIN* (*PARK2*) are involved in mitochondrial homeostasis and stress responses ([@bib14], [@bib23], [@bib30]). PARK1/4 is involved in α-synuclein accumulation, which is the pathological feature of PD ([@bib23]), and PARK8 has also been reported to be associated with impaired autophagy. However, the findings obtained from cellular models and animal models do not always accurately reflect the pathogenesis of PD patients due to different cellular contexts or vulnerability to disease-relevant mutations ([@bib3]). Therefore, despite these advances, no effective therapeutic treatments have been developed.

The recent progress of human induced pluripotent stem cell (iPSC)-assisted technology presents new opportunities for disease modeling based on precise cellular contexts, which had previously been difficult to obtain, especially in neurodegenerative disorders ([@bib31]). In the case of PD, patient-derived iPSCs would be a direct source for midbrain DA neurons, a disease-relevant cell type. Accordingly, there has been a series of studies demonstrating disease-relevant phenotypes using PD-derived iPSCs ([@bib11]). Although these studies have elegantly demonstrated disease-related phenotypes, a more efficient protocol to generate DA neurons from patient-derived iPSCs would lead to the identification of mechanisms whereby PD patients develop DA-neuron-specific phenotypes.

Here, we developed an efficient directed differentiation protocol to generate DA neurons with less variation of efficacy than previous protocols ([@bib22], [@bib35], [@bib40]). We used PARK2 patient-specific and isogenic *PARK2* null (*PARK2*^−/−^) iPSC-derived DA neurons (PARK2-DA neurons and *PARK*2^−/−^-DA neurons, respectively) for *in vitro* disease modeling and found that these neurons exhibited neurite abnormalities, elevated oxidative stress, and apoptosis. We also performed a phenotypic screening to identify neuroprotective compounds and identified benidipine, a voltage-gated calcium channel antagonist, as a potential chemical targeting PD. Importantly, we found that the selective vulnerability of DA neurons to rotenone-induced stress in PARK2 was attributable to the dysregulation of intracellular calcium homeostasis via T-type calcium channels. In summary, we have established a robust platform to model PD in a dish and revealed an additional layer of the pathogenesis of PD, offering a potential therapeutic target.

Results {#sec2}
=======

Characterization of Dopaminergic Neurons Derived from PARK2 Patient-Specific and Isogenic *PARK2*^−/−^ iPSC Lines {#sec2.1}
-----------------------------------------------------------------------------------------------------------------

In an attempt to identify the chemical compounds for PD, we developed an efficient directed differentiation protocol to establish an *in vitro* disease model using PD patient-specific iPSC-derived DA neurons ([Figure 1](#fig1){ref-type="fig"}A). As a feature of this protocol, it is possible to use cryopreserved neural progenitor cells (NPCs), which enables us to perform stable differentiation induction, reproducible disease phenotypic analysis, and compound screening in a large number of cells with a uniform frozen cell lot. As an entry point, NPCs were generated from the iPSCs established from two PARK2 patients, PA and PB ([Figure 1](#fig1){ref-type="fig"}B). For comparison, NPCs derived from control iPSCs were also used ([Figure 1](#fig1){ref-type="fig"}B). In addition, iPSC-NPCs derived from a *PARK2*^−/−^ iPSC line (B7PA21) were also generated to evaluate the disease-relevant phenotypes in the same genetic background ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}). We initially examined the cellular properties after the differentiation of iPSC-NPCs toward midbrain DA neurons. As shown in [Figure 1](#fig1){ref-type="fig"}C, the efficiency of neuronal differentiation was assessed on differentiation day 14 by the number of cells positive for neuronal markers including βIII-tubulin and microtubule-associated protein 2 (MAP2); βIII-tubulin^+^ neurons constituted approximately 84% of the total cells among all the lines. In our protocol, there were very few glial fibrillary acidic protein (GFAP)^+^ cells, indicating that astrocytic differentiation was negligible. Importantly, tyrosine hydroxylase (TH)^+^ neurons constituted more than 40% of the βIII-tubulin^+^ neurons ([Figure 1](#fig1){ref-type="fig"}C). The proportions of βIII-tubulin^+^ TH ^+^ neurons to the total population did not change significantly between PARK2 patient lines and control lines, indicating the consistency of DA neuron generation in our protocol. We further characterized TH^+^ neurons with midbrain markers, including forkhead box protein A2 (FOXA2), engrailed-1 (EN1), nur-related factor 1 (NURR1), and G-protein-activated inward rectifier potassium channel 2 (GIRK2) ([@bib20], [@bib53]), further confirming the production of dopamine on day 14 by immunocytochemical analysis ([Figure 1](#fig1){ref-type="fig"}D). Because we detected electrophysiological activity in the neurons on day 14 by recording using an Axion MEA system ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2E), we extended our analysis to demonstrate the functional properties of the neurons by measuring dopamine release. To demonstrate the functional properties of these DA neurons, we measured dopamine release by ELISA. We found that the amount of spontaneous dopamine release was increased during neuronal differentiation ([Figure 1](#fig1){ref-type="fig"}E). Furthermore, no difference was observed between the DA neurons derived from a control line (Cont A) and a PARK2 line (PB) in regard to dopamine release on day 14 ([Figure 1](#fig1){ref-type="fig"}F). Taken together, we could develop an efficient and robust differentiation protocol for the generation of midbrain DA neurons from NPCs.Figure 1Characterization of Dopaminergic Neurons Derived from PARK2 Patient-Specific and Isogenic *PARK2*^−/−^ iPSC Lines(A) Experimental paradigm for differentiation of human iPSC-derived NPCs toward DA neurons. Scale bars, 100 μm.(B) Properties of iPSC-derived NPCs from the Control A (AF22), Control B (201B7), *PARK2*^−/−^ (B7PA21), PA (PA9), and PB (PB2) lines. Immunocytochemical staining was performed with antibodies against neural stem cell-associated markers (SOX1, SOX2, DACH1, and nestin). Scale bar, 100 μm.(C) Quantitative analyses of cells positive for βIII-tubulin, MAP2, TH, and GFAP. Data represent the means ± SEM (n = 4--6 independent biological replicates).(D) Characterization of DA neurons from Control A, Control B, *PARK2*^−/−^, PA, and PB at differentiation day 14. Immunocytochemical staining was performed with antibodies against neuronal markers (βIII-tubulin and MAP2), an astrocytic marker (GFAP), a dopaminergic neuron marker (TH), midbrain markers (FOXA2, EN1, NURR1, and GIRK2) and dopamine. Insets are the images of GFAP^+^ signals. Scale bar, 100 μm.(E) Quantification of dopamine released from control iPSC (Control B)-derived DA neurons. Data represent the means ± SEM (n = 4 independent biological replicates).(F) A comparison of the levels of dopamine released by DA neurons from Control A and PB on day 14. Data represent the means ± SEM (n = 5 independent biological replicates).(G) Neurite length was examined in the DA neurons derived from Control A and PARK2 patient-specific NPCs (PB and PA) on day 14. Quantification of the neurite length is shown (right). Data represent the means ± SEM (n = 4--10 independent biological replicates). ^∗∗∗^p \< 0.001 by an unpaired t test. Scale bar, 100 μm.(H) Neurite length was examined in DA neurons derived from a *PARK2*^−/−^ line and the parental line (Control B) on day 14. Quantification is shown (right). Data represent the means ± SEM (n = 4 independent biological replicates). ^∗∗∗^p \< 0.001 by an unpaired t test. Scale bar, 100 μm.(I) Elevated intracellular oxidative stress in PARK2- and *PARK2*^−/−^-DA neurons. Intracellular oxidative stress was assessed in DA neurons on day 14 with an indicator, CellROX. Representative images of CellROX^+^ signals in the DA neurons are shown (left). Insets are the images of CellROX^+^ signals. Scale bar, 20 μm. Quantification is shown (right). Data represent the means ± SEM (n = 3 independent biological replicates). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 by Dunnett\'s multiple comparison test.(J) The abundance of apoptotic cells was increased in PARK2- and *PARK2*^−/−^-DA neurons on day 14. Representative images of cleaved caspase-3 (CASP3) immunostaining are shown (left). Scale bar, 20 μm. Quantification is shown (right). Data represent the means ± SEM (n = 7--10 independent biological replicates). ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 by Dunnett\'s multiple comparison test.

Moreover, given the observed axonal degeneration of DA neurons of the SN in PD patients ([@bib5]) and reduced morphological complexity of iPSC-derived DA neurons from PD patients ([@bib35]), we examined the neuronal morphology by measuring the neurite length of DA neurons on day 14 ([Figure S2](#mmc1){ref-type="supplementary-material"}F). As shown in [Figure 1](#fig1){ref-type="fig"}G, the neurons derived from PARK2 iPSC-NPCs exhibited reduced neuronal processes compared with those of a control iPSC-NPC line as judged by βIII-tubulin staining. This phenotype was also observed in the DA neurons derived from the *PARK2*^−/−^ iPSC line ([Figure 1](#fig1){ref-type="fig"}H), indicating that the morphological abnormality of the DA neurons was caused by a mutation in the *PARK2* gene. Oxidative stress plays a key role in the selective degeneration of SN DA neurons in PD ([@bib10], [@bib12]), and we previously showed the presence of elevated oxidative stress levels in PARK2 iPSC-derived neurons ([@bib22]). Therefore, we next investigated whether the oxidative stress levels were also increased in the PARK2- or *PARK2*^−/−^-DA neurons by using CellROX Green Reagent to measure the intracellular oxidative stress levels ([Figure S2](#mmc1){ref-type="supplementary-material"}F). The proportion of CellROX^+^ cells was significantly increased in the PARK2- and *PARK2*^−/−^-DA neurons compared with the control DA neurons, indicating increased intracellular oxidative stress levels in the DA neurons in PD ([Figures 1](#fig1){ref-type="fig"}I and [S2](#mmc1){ref-type="supplementary-material"}G), consistent with a previous report ([@bib6]). We further investigated the cell viability of PARK2- or *PARK2*^−/−^-DA neurons by the expression of cleaved caspase-3 (CASP3), which labels apoptotic cells ([Figure S2](#mmc1){ref-type="supplementary-material"}F). As shown in [Figures 1](#fig1){ref-type="fig"}J, [S2](#mmc1){ref-type="supplementary-material"}H, and [S3](#mmc1){ref-type="supplementary-material"}B, we found a significant increase in the apoptotic cell population among PARK2- and *PARK2*^−/−^-DA neurons. Although we demonstrated increased oxidative stress and apoptosis in the PARK2-DA neurons after the purification of DA neuronal progenitors using fluorescence-activated cell sorting ([@bib48]), our current procedures enabled us to simplify the differentiation steps to generate DA neurons. Utilizing isogenic *PARK2*^−/−^ lines in parallel with patient-derived lines, we could demonstrate that loss of *Parkin* function in PD triggered cellular stress and cell death in DA neurons.

PARK2-Dopaminergic Neurons Showed Increased Susceptibility to Rotenone-Induced Stress {#sec2.2}
-------------------------------------------------------------------------------------

Because it has been reported that mitochondrial respiratory chain complex I activity is reduced in the brains of PD patients ([@bib38], [@bib52]), we used rotenone, a mitochondrial complex I inhibitor ([@bib13]), to mimic environmental toxicity to mitochondria. We speculated that a combination of genetic mutations and environmental toxicity would be important for developing a disease model to suppress the pathological progression of PD. Accordingly, we compared the susceptibility of the control and PARK2-DA neurons to the rotenone treatment. The DA neurons were treated with rotenone (10 μM) for 3 hr or 24 hr and analyzed for intracellular oxidative stress and apoptotic cells, respectively. As expected, the rotenone-exposed PARK2-DA neurons exhibited higher oxidative stress levels than the control DA neurons ([Figure 2](#fig2){ref-type="fig"}A). Furthermore, we observed higher rates of CASP3^+^ apoptotic DA neurons in the rotenone-exposed PARK2 lines than in the control lines ([Figure 2](#fig2){ref-type="fig"}B). The enhanced apoptosis in the PARK2-DA neurons was further evaluated and confirmed by an *in situ* TUNEL analysis ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). We also detected the vulnerability of the mitochondrial membrane potential among the rotenone-exposed PARK2-DA neurons ([Figure S3](#mmc1){ref-type="supplementary-material"}C). In addition, to determine whether the effect of rotenone was specific to DA neurons, we also performed the same analysis on TH^−^ βIII-tubulin^+^ neurons. Interestingly, TH^−^ neurons were less susceptible to rotenone-induced apoptosis, and there was no significant difference between the control and patient-derived neurons, indicating selective susceptibility of the DA neurons to rotenone-induced stress, which further supports subtype-specific neuronal loss in PD. In the following analysis, given there is an increased dynamic range of disease-related phenotypes by rotenone treatment, we applied the experimental paradigm to proceed with chemical screening to identify the compounds that reduce the disease-related phenotypes.Figure 2PARK2-Dopaminergic Neurons Showed Increased Susceptibility to Rotenone-Induced Stress(A) Enhancement of the CellROX^+^ fraction by rotenone treatment in PARK2-DA neurons on day 14. Representative staining images of CellROX^+^ cells with or without rotenone exposure (10 μM, 3 hr) are shown (left). Insets are the images of CellROX^+^ signals. Quantification is shown (right). Data represent the means ± SEM (n = 3--10 independent biological replicates). ^∗^p \< 0.05, ^∗∗∗^p \< 0.001 by Tukey\'s multiple comparison test. Scale bar, 20 μm.(B) Immunocytochemical analysis of CASP3^+^ cells in DA neurons on day 14 with or without rotenone treatment (10 μM, 24 hr). Cells marked as TH^−^ neurons represent the population of TH^−^ and βIII-tubulin^+^ neurons. Quantification of apoptotic cells in TH^+^ neurons and TH^−^ neurons. Data represent the means ± SEM (n = 3--6 independent biological replicates). ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 by Tukey\'s multiple comparison test. Scale bar, 20 μm.

A Calcium Channel Antagonist Prevented Rotenone-Induced Apoptosis and Rescued Impaired Neurite Outgrowth in PARK2-Dopaminergic Neurons {#sec2.3}
--------------------------------------------------------------------------------------------------------------------------------------

To evaluate whether *in vitro* disease modeling using PARK2-DA neurons could be used as a system for drug discovery, we further explored the compounds that reduce the vulnerability of DA neurons. To repurpose existing drugs, we conducted an initial screening with an FDA-approved drug library containing 1,165 compounds ([Figure 3](#fig3){ref-type="fig"}A) ([@bib42]). In the initial screening, 88 compounds were selected because the CASP3 levels in the treated DA neurons were less than 50% of the levels in the neurons treated with only rotenone ([Figure 3](#fig3){ref-type="fig"}B). Then, we classified the compounds into several subgroups according to their major pharmacological effects, such as calcium channel antagonists (CCAs), cardiovascular drugs, and antibiotic/antiparasitic drugs ([Figure S4](#mmc1){ref-type="supplementary-material"}A). The category of CCAs was attractive considering the number of confirmed hit compounds. For example, benidipine (a dihydropyridine \[DHP\]-derived triple L-, N-, and T-type CCA) strongly reduced rotenone-induced apoptosis ([Figure 3](#fig3){ref-type="fig"}C) ([@bib26], [@bib55]). In addition, cinnarizine (a phenylpiperazine-derived dual L- and T-type CCA) ([Figure S4](#mmc1){ref-type="supplementary-material"}B) ([@bib7]) and amiodarone (a benzofuran-derived dual L- and T-type CCA) ([@bib7]) also displayed neuroprotective effects in the PARK2-DA neurons ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Because these compounds exhibited diverse chemical structures while being categorized in the same category, their neuroprotective effects seemed to be mechanism dependent. However, nifedipine (a DHP-derived selective L-type CCA) ([@bib8]) and isradipine (a DHP-derived selective L-type CCA) ([@bib36]), the same DHP analogs as benidipine, failed to prevent rotenone-induced apoptosis ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E), indicating that the calcium channel subtype is important for neuroprotective effects against PARK2-DA neurons. This finding is slightly contradictory to the previous observation that L-type calcium channels, especially the CaV1.3 subtype, generate an activity-related oscillatory calcium burden in SN DA neurons, contributing to their degeneration and the pathology of PD ([@bib21], [@bib47]). Because the presence of T-type calcium channels in DA neurons remains unclear, we conducted the analysis using a selective T-type calcium channel antagonist, ML218 ([@bib54]). As expected, ML218 suppressed rotenone-induced apoptosis in the PARK2-DA neurons ([Figure 3](#fig3){ref-type="fig"}D). These results indicated that T-type calcium channels contribute to rotenone-induced apoptosis in the PARK2-DA neurons. Next, to confirm whether benidipine is neuroprotective, we investigated its effect on neurite abnormalities in PARK2-DA neurons and found that benidipine also rescued impaired neurite outgrowth in PARK2-DA neurons ([Figure 3](#fig3){ref-type="fig"}E). Taken together, the results from our screening system using PARK2-DA neurons identified some existing drugs that have potential neuroprotective effects as well as new candidate therapeutic target pathways.Figure 3A Calcium Channel Antagonist Protected against Rotenone-Induced Apoptosis and Rescued Impaired Neurite Outgrowth in PARK2-Dopaminergic Neurons(A) Experimental paradigm to identify chemical compounds targeting PD. PARK2-DA neurons (PB) were exposed to rotenone (10 μM) or DMSO for 24 hr. In the compound screening, the DA neurons were treated with test compounds (10 μM) in duplicate for 24 hr prior to rotenone treatment.(B) Representative data from initial screening. The vertical axis shows the inhibitory effect of the test compounds on rotenone-induced apoptosis. Each dot represents an individual compound. The red line indicates 50% of the control value. Eighty-eight of 1,165 compounds were found to reduce CASP3 levels to \<50% (% of rotenone-exposed PARK2-DA neuron count).(C and D) Protective effects of (C) benidipine and (D) ML218 on rotenone-mediated (10 μM, 24 hr) apoptosis. Representative images of CASP3^+^ cells in DA neurons are shown (left). Insets are the images of CASP3^+^ signals. Data represent the means ± SEM (n = 3--16 independent biological replicates). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 by Dunnett\'s multiple comparison test. Scale bar, 100 μm.(E) Neurite length was examined in the control and PARK2-derived neurons treated with DMSO or benidipine (10 μM) for 6 days. Quantification of the neurite length is shown (right). Data represent the means ± SEM (n = 4 independent biological replicates). ^∗^p \< 0.05, ^∗∗^p \< 0.01 by a t test with Sidak\'s correction.

A Calcium Channel Antagonist Displayed Neuroprotective Effects against Dopaminergic Neurons Derived from a PARK6 Patient-Specific iPSC Line {#sec2.4}
-------------------------------------------------------------------------------------------------------------------------------------------

To further validate the effect of benidipine on PD patient-derived DA neurons, we examined its effect on the DA neurons generated from different PD patient-derived DA neurons. We utilized a different form of familial PD with a mutation of PARK6. PARK6 encodes PINK1, a mitochondria-targeted kinase thought to play an important role in mitochondrial homeostasis together with PARKIN ([@bib39]). Importantly, the DA neurons derived from PARK6 patient-specific iPSCs were reported to display several PD phenotypes, including cell-type-specific vulnerability and mitochondrial dysfunction ([@bib6]). We generated NPCs from PARK6 patient-specific iPSCs ([@bib41]) and differentiated them into DA neurons. The PARK6 iPSC-NPCs were also competent with differentiation toward DA neurons, and the PARK6 iPSC-NPC-derived DA neurons (PARK6-DA neurons) displayed several markers of DA neurons ([Figure 4](#fig4){ref-type="fig"}A). As observed in the PARK2-DA neurons, the PARK6-DA neurons displayed shortened neurite lengths and elevated oxidative stress levels compared with the control DA neurons ([Figures 4](#fig4){ref-type="fig"}B and 4C). Furthermore, the rotenone treatment also enhanced the oxidative stress levels and apoptosis in the PARK6-DA neurons ([Figures 4](#fig4){ref-type="fig"}C and 4D), indicating that disease-specific phenotypes could also be reconstructed in DA neurons derived from PARK6 iPSC lines. Finally, we examined the neuroprotective effects of benidipine on PARK6-DA neurons; we found that benidipine protected the DA neurons from rotenone-induced stress in a concentration-dependent manner ([Figure 4](#fig4){ref-type="fig"}E) and rescued impaired neurite outgrowth ([Figure 4](#fig4){ref-type="fig"}F). Taken together, our results show that the neuroprotective effect of benidipine on PD-derived DA neurons was highly specific to disease-relevant abnormality in PD patients.Figure 4A Calcium Channel Antagonist Displayed Neuroprotective Effects in Dopaminergic Neurons Derived from a PARK6 Patient-Specific iPSC Line(A) Representative images of iPSCs, NPCs, and DA neurons derived from a PARK6 patient with *PINK1* mutations (PKB3). The expression of four neural stem cell-related markers, including SOX1, SOX2, DACH1, and nestin, indicated that the cells are neural stem cells. PARK6-DA neurons on day 14 expressed DA neuron markers, such as βIII-tubulin, MAP2, TH, FOXA2, EN1, and GIRK2. Scale bar, 100 μm.(B) Reduced neurite length in PARK6-DA neurons on day 14 compared with the control (Control A). Quantification of neurite length is shown. Data represent the means ± SEM (n = 4 independent biological replicates). ^∗∗^p \< 0.01 by an unpaired t test.(C) Immunocytochemical analysis of CellROX^+^ cells in DA neurons (Control A and PARK6) on day 14 with or without rotenone treatment (10 μM, 3 hr). Data represent the means ± SEM (n = 3 independent biological replicates). ^∗∗^p \< 0.01 by Tukey\'s multiple comparison test.(D) Immunocytochemical analysis of CASP3^+^ cells in DA neurons (Control A and PARK6) on day 14 with or without rotenone treatment (10 μM, 24 hr). Data represent the means ± SEM (n = 3 independent biological replicates). ^∗∗∗^p \< 0.001 by Tukey\'s multiple comparison test.(E) The PARK6-DA neurons were treated with benidipine 24 hr prior to rotenone treatment (10 μM, 24 hr). Data represent the means ± SEM (n = 6--12 independent biological replicates). p value was calculated by Dunnett\'s multiple comparison test.(F) Neurite length was examined in the control (Control A) and PARK6-DA neurons treated with DMSO or benidipine (10 μM) for 6 days. Data represent the means ± SEM (n = 4 independent biological replicates). ^∗^p \< 0.05 by a t test with Sidak\'s correction.

Dysregulation of Calcium Homeostasis in PARK2-Dopaminergic Neurons Was Suppressed by Selective T-type Calcium Channel Inhibition {#sec2.5}
--------------------------------------------------------------------------------------------------------------------------------

Considering the function of benidipine, it is likely that the dysregulation of cellular calcium homeostasis might result in the vulnerability of DA neurons in PD. Previous works in mouse SN DA neurons have shown that T-type calcium channels are present and functionally important ([@bib15], [@bib43]). Therefore, we examined the expression of the voltage-gated calcium channel in DA neurons. Interestingly, we observed higher expression of the T-type calcium channels (CaV3.1, CaV3.2, and CaV3.3) in PARK2-DA neurons than in control DA neurons ([Figures 5](#fig5){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A). We then utilized the calcium indicator dye Fluo-8 AM to examine the intracellular calcium levels in PARK2-derived neurons. As shown in [Figure 5](#fig5){ref-type="fig"}B, the neurons derived from the PARK2 iPSC lines had increased resting calcium levels compared with the control line (PARK2 including PB and PA, 174% increase compared with the control; ^∗^p \< 0.05 by an unpaired t test, n = 4--8 independent biological replicates). In addition, we observed significantly increased intracellular calcium levels in the rotenone-treated PARK2 iPSC lines ([Figure 5](#fig5){ref-type="fig"}B). Furthermore, benidipine and ML218 inhibited rotenone-induced intracellular calcium increases in the PARK2-derived neurons ([Figure 5](#fig5){ref-type="fig"}C), indicating that T-type calcium channels contribute to the dysregulation of calcium homeostasis in PARK2-DA neurons. To gain insight into the functional role of T-type calcium channels, we performed a loss-of-function analysis using small interfering RNAs (siRNAs) against T-type calcium channels and examined their effects on DA neurons. Initially, we examined the expression level of mRNA and protein of each channel after the introduction of siRNAs into the DA neurons and found reduced expression of each subunit of the channel in the DA neurons ([Figures 5](#fig5){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}C). Then, we introduced the siRNA into the PARK2-DA neurons, exposed them to rotenone, and assessed their intracellular calcium levels using Fluo-8 AM. We found that knockdown of any individual T-type calcium channel subtype resulted in a tendency to decrease the calcium levels ([Figure S5](#mmc1){ref-type="supplementary-material"}E). In addition, immunocytochemical analysis for CASP3 revealed that knockdown of T-type calcium channels suppressed rotenone-induced apoptosis in the PARK2-DA neurons ([Figure 5](#fig5){ref-type="fig"}E). These phenotypes were also observed in the DA neurons derived from the *PARK2*^−/−^ iPSC line ([Figures S5](#mmc1){ref-type="supplementary-material"}B, S5D, and 5F). To further validate our findings about the dysregulated expression of T-type calcium channels, we overexpressed T-type calcium channels (CaV3.1 and CaV3.3) into control DA neurons to examine whether a dysregulated intracellular calcium concentration triggers PD-like phenotypes in the control DA neurons. Interestingly, the overexpression of T-type calcium channels triggered increased susceptibility of the DA neurons to rotenone-induced stress ([Figures S5](#mmc1){ref-type="supplementary-material"}F--S5H). These results suggest that the selective vulnerability of DA neurons to rotenone-induced stress in PARK2 was attributable to the dysregulation of intracellular calcium homeostasis via the T-type calcium channels.Figure 5Dysregulation of Calcium Homeostasis in PARK2-Dopaminergic Neurons was Suppressed by Selective T-type Calcium Channel Inhibition(A) Immunocytochemistry was performed on day 14 for the T-type calcium channel subtypes (CaV3.1, CaV3.2, and CaV3.3). Representative image of calcium channel subtypes in DA neurons (left). The relative expression levels of calcium channel subtypes are shown (right). Data represent the means ± SEM (n = 4 independent biological replicates). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 by a t test with Sidak\'s correction. Scale bar, 20 μm.(B) Measurement of intracellular calcium levels of neurons (Control A, PB, and PA) on day 14 with or without rotenone treatment (10 μM, 24 hr) by the fluorescent calcium indicator Fluo-8 AM. Data represent the means ± SEM (n = 3--4 independent biological replicates). ^∗∗∗^p \< 0.001 by Tukey\'s multiple comparison test.(C) The effect of CCAs on the intracellular calcium concentration in PARK2-DA neurons (PB). The cells were exposed to benidipine (1 μM) or ML218 (1 μM) 24 hr prior to rotenone treatment. Data represent the means ± SEM (n = 3--6 independent biological replicates). ^∗^p \< 0.05, ^∗∗^p \< 0.01 by Dunnett\'s multiple comparison test.(D) Knockdown was performed on day 14 with transient siRNA transfection, Accell siRNA (1 μM) against T-type calcium channel subtypes for 72 hr in the control DA neurons (Control B), and verified with qRT-PCR. Values were normalized to the expression of GAPDH, and changes in mRNA levels were measured relative to non-targeting control siRNA levels. Data represent the means ± SEM (n = 3 independent biological replicates). ^∗^p \< 0.05, ^∗∗^p \< 0.01 by an unpaired t test.(E and F) Requirement of T-type calcium channel subtypes for the vulnerability of (E) PARK2 (PB)- and (F) *PARK2*^−/−^-DA neurons. The cells were transfected with siRNA against the various T-type calcium channel subtypes for 72 hr prior to rotenone treatment. Immunocytochemical analysis of the CASP3^+^ cells in DA neurons on day 14 with rotenone treatment (10 μM, 24 hr). Representative image of CASP3^+^ cells in PARK2-DA neurons are shown (left). Data represent the means ± SEM (n = 3 independent biological replicates). ^∗^p \< 0.05, ^∗∗^p \< 0.01 by Dunnett\'s multiple comparison test. Scale bar, 20 μm.

Discussion {#sec3}
==========

Because various therapeutic strategies have failed to yield a promising treatment for the disease processes of PD ([@bib1]), it is important to establish model systems for developing more effective therapeutic interventions; such systems would be a bridge between animal models and human patients. A postmortem analysis is informative regarding the end-stage pathology of PD, but understanding the early molecular changes associated with the initiation of PD is required to develop improved therapies to halt the progression of the disease. A model system that faithfully reflects the pathogenesis of PD would support the development of more effective therapies. In this respect, PD patient-derived iPSCs represent a useful tool for *in vitro* disease modeling. In parallel with the analysis using isogenic *PARK2*^−/−^ iPSCs ([Figures 1](#fig1){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}), we established a robust and well-controlled *in vitro* culture system and demonstrated several PD-related phenotypes, including neurite abnormalities, elevated oxidative stress, and apoptosis in PARK2- and *PARK2*^−/−^-DA neurons ([Figures 1](#fig1){ref-type="fig"}, [S2](#mmc1){ref-type="supplementary-material"}, and [S3](#mmc1){ref-type="supplementary-material"}B). Although several PD-related phenotypes have been reported in PARK2 iPSCs ([@bib22], [@bib35], [@bib40]), the frequency of DA neurons within the entire neuronal population in these studies is either unmentioned or less than 15%. In contrast, we have successfully generated DA neurons from iPSC lines, and the DA neurons further exhibited midbrain regional specificity and dopamine production ([Figure 1](#fig1){ref-type="fig"}). Recently, we also reported a method for preparing highly enriched DA neurons using fluorescence-activated cell sorting ([@bib48]), but the current procedure is more advanced in terms of simplicity and robustness for neuronal differentiation, enabling us to perform screening without complicated work.

Notably, we further extended our study to screen CCAs based on their effects on rotenone-treated PARK2-DA neurons ([Figures 3](#fig3){ref-type="fig"} and [S4](#mmc1){ref-type="supplementary-material"}). It is noteworthy that selectivity for calcium channel subtypes may be associated with differences in neuroprotective effects in different DHP analogs, such as benidipine, nifedipine, and isradipine. We also validated the results obtained from PARK2-DA neurons in the DA neurons derived from PARK6 iPSCs ([Figure 4](#fig4){ref-type="fig"}). Mechanistically, loss-of-function mutations in PARK2 or PARK6 have been associated with mitochondrial dysfunction, including reduced ATP production, impaired mitochondrial autophagy, mitophagy, and disruption of intracellular calcium homeostasis ([@bib6], [@bib37]). Mitochondria are important temporal and spatial regulators of intracellular calcium concentrations in neurons, and mitochondrial dysfunction triggers mitochondrial permeability transition pore opening via high mitochondrial calcium levels and mitochondrial depolarization. The opening of pores releases apoptotic factors and leads to apoptosis ([@bib4]). In the present report, we observed selective upregulation of T-type calcium channels in PARK2-DA neurons. Regarding the relationship between calcium channels and PD pathogenesis, SN DA neurons are reported to be autonomous pacemakers that fire action potentials in the absence of excitatory synaptic input; this pacemaker activity is mainly regulated by the L-type calcium channel CaV1.3, as revealed by an animal model ([@bib47]). This function is consistent with the potential beneficial effect of certain CCAs---specifically, inhibitors of L-type calcium channels---against PD, as revealed by etiological observations in patients using CCAs as an antihypertensive intervention ([@bib36]). Although the potential neuroprotective role of isradipine has been reported ([@bib45], [@bib46]), the plasma concentration of isradipine approved for therapy has been reported to be insufficient for the treatment of a PD animal model ([@bib32]). Furthermore, only modest advantages were achieved in a recent clinical trial (STEADY-PD) ([@bib33]). Therefore, the efficacy of isradipine remains controversial, and the results of an ongoing phase 3 clinical trial (STEADY-PD III) are awaited to reach a definitive conclusion about its effectiveness against PD ([@bib46]). On the other hand, at least in our experimental model, the dysregulation of L-type calcium channels is less likely to contribute to the pathogenesis of PD. Furthermore, [@bib16] showed, using mouse brain slices, that SN DA neurons negative for the calcium buffering protein calbindin are highly vulnerable compared with calbindin^+^ SN neurons. In addition, calbindin^−^ DA neurons have a higher density of T-type calcium channels than calbindin^+^ DA neurons. However, because of the limited availability of suitable models, there is no direct evidence linking selective vulnerability with T-type calcium channels in the PD brain to date. Therefore, iPSC-based disease modeling provides a versatile *in vitro* system to evaluate the pathogenesis of neurodegenerative disease. One might wonder about the validity of the concentration of the compound we applied in our experiment compared with the clinical dosage of the compound. As the neuroprotective dose of benidipine (50% inhibitory concentration \[IC~50~\] = 1.1 μM; 95% confidence interval, 0.2 to 6.7 μM; n = 9 independent biological replicates) in the rotenone-exposed cell-based assay was found to be similar to the therapeutic range of this drug in clinical use (3.7--7.4 μM as an antihypertensive) ([@bib26]), this compound may be suitable for new therapeutic purposes, such as PD treatment, and T-type CCAs are strong candidates for disease-modifying drugs that can alleviate the progressive pathology of PD ([Figure 6](#fig6){ref-type="fig"}). Although we utilized DA neurons from PAKR2 and PARK6 iPSCs, we cannot rule out the possibility that the neuroprotective effect of benidipine is specific to DA neurons with an abnormal PINK1-PARKIN pathway. Furthermore, in our experimental model for drug screening, we utilized rotenone to enhance the disease-related phenotypes. Enhancement of the *in vitro* phenotype was also achieved in other chemical compounds such as carbonyl cyanide m-chlorophenylhydrazone (CCCP), an uncoupler that is known to dissipate mitochondrial membrane potential and induced entry of extracellular calcium through L/N-type calcium channels ([@bib19]). Similar to the effects of rotenone, we observed an increased proportion of TH^+^ neurons co-expressing CASP3, and CCCP-induced cell death was suppressed by the addition of benidipine ([Figure S6](#mmc1){ref-type="supplementary-material"}). Therefore, future research will clarify the effect of benidipine on other types of PD patient-derived DA neurons.Figure 6Calcium Homeostasis Dysregulation Triggers Selective Vulnerability of Dopaminergic Neurons to Rotenone-Induced Stress in PARK2Schematics of calcium homeostasis dysregulation in PARK2-DA neurons. When normal DA neurons were exposed to rotenone, damaged mitochondria were removed by Parkin- and PINK1-mediated mitophagy, allowing normal function to be maintained. However, mitochondrial function could not be restored due to the abnormality of the mitochondrial quality control mechanism in rotenone-exposed PARK2-DA neurons. Therefore, intracellular calcium overload promoted mitochondrial dysfunction and caused cell death specifically in DA neurons. Selective inhibition of T-type calcium channels suppressed the increase in intracellular calcium levels and cell death.

Because dysregulated mitochondrial function occurs ubiquitously in the PD brain, additional cell-intrinsic circumstances in midbrain DA neurons might determine cell-type-specific vulnerability, triggering selective death of DA neurons in PD patients. For example, transcriptional regulation of T-type calcium channels in DA neurons is of interest based on our findings that the PARK2-DA neurons expressed more T-type calcium channels ([Figures 5](#fig5){ref-type="fig"} and [S5](#mmc1){ref-type="supplementary-material"}). In contrast with increased intracellular calcium levels after rotenone treatment ([Figure 5](#fig5){ref-type="fig"}B), the mRNA level of calcium channels did not change after rotenone treatment, indicating that transcriptional regulation is less likely to contribute to dysregulated intracellular calcium levels in PARK2-DA neurons. Because there is limited information to date on the regulation of those channels, we would like to address this matter experimentally in our future studies. Given that the dysregulation of calcium homeostasis plays a pivotal role in the pathogenesis of several neurodegenerative diseases, including PD ([@bib2], [@bib45]), Alzheimer disease ([@bib2], [@bib28]), Huntington disease ([@bib2], [@bib25]), and amyotrophic lateral sclerosis ([@bib2], [@bib27]), it would be important to unravel the contribution of dysregulated calcium channels in these diseases and how a dysregulated calcium concentration triggers selective neuronal deaths in other types of neuronal subsets.

In summary, our study indicates that PARK2-DA neurons provide an *in vitro* disease model that recapitulates several PD-related disease phenotypes; this model can be used to investigate the pathogenesis of the disease and search for potential therapeutic targets for PD.

Experimental Procedures {#sec4}
=======================

A detailed description of the experimental procedures is given in the [Supplemental Information](#app2){ref-type="sec"}.

Generation of Patient-Specific and Isogenic iPSC-Derived Neural Progenitor Cells {#sec4.1}
--------------------------------------------------------------------------------

The iPSC line 201B7 ([@bib49]), PARK2 iPSC lines PA9 and PB2 ([@bib22]), PARK2-deficient iPSC lines (B7PA21) ([@bib44]), and PARK6 iPSC line PKB3 ([@bib41]) were established and maintained as previously described. The NPCs were established from the 201B7, PA9, PB2, PKB3, and B7PA21 iPSC lines as previously described ([@bib17]).

Compound Screening {#sec4.2}
------------------

We used an FDA-approved drug library consisting of 1,165 biologically active compounds ([@bib42]). The PARK2-DA neurons were incubated for 48 hr in the absence or presence of each compound (10 μM); subsequently, rotenone (10 μM) treatment was conducted for 24 hr ([Figure 3](#fig3){ref-type="fig"}A).

Statistical Analysis {#sec4.3}
--------------------

Statistical analysis was performed using GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA). The data are described as the means ± standard error of the mean (SEM). Unpaired t tests were used for pairwise comparisons between the groups. One-way analysis of variance (ANOVA) followed by Dunnett\'s test and two-way ANOVA followed by either Tukey\'s test or a t test with Sidak\'s correction were applied for multiple comparisons. The results were considered statistically significant when p \< 0.05. The IC~50~ was also calculated using GraphPad Prism.
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